Samaritan gets Amphocil MAA in Cyprus
Las Vegas, USA-based Samaritan Pharmaceuticals, Inc. that its European subsidiary has received notification from the Cyprus Ministry of Health that its marketing authorization for the HIV fungus drug Amphocil (amphotericin) has been approved in Cyprus.
Eugene Boyle, chief executive of Samaritan, stated: "we anticipate starting sales of Amphocil in Cyprus shortly after we establish an official price with the Minister of Health. It is exciting to see Samaritan's business strategy to sell approved specialty drugs in Greece and Eastern Europe, expanding and growing revenue opportunities."
Amphocil, an injection, is a lipid form of amphotericin B indicated for the treatment of invasive aspergillosis, a life threatening systemic fungal infection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze